- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Elscint names Sardano to NM post
Israeli multimodality vendor Elscint has named Joe Sardano head of its U.S. nuclear medicine business unit, a position that previously had been vacant. Prior to joining Elscint in November, Sardano was with Fisher Scientific, and has also worked for
Israeli multimodality vendor Elscint has named Joe Sardano head of its U.S. nuclear medicine business unit, a position that previously had been vacant. Prior to joining Elscint in November, Sardano was with Fisher Scientific, and has also worked for Park, Toshiba, and Diasonics. Sardano said his priorities in the position are to expand Elscint's sales force, broaden the company's marketing efforts, and improve the vendor's customer satisfaction levels in the U.S.
Sardano will report to Eliezer Tokman, the Elscint CT veteran who was named to head the company's Americas regional operations in a restructuring announced in November (SCAN 11/12/97). Elscint is moving its global nuclear medicine headquarters to the U.S. as part of the restructuring.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
